Abstract
The surfaces of the abdomen and pelvis are an important anatomic site for the dissemination of gastrointestinal and gynecologic malignancy. This transcoelomic spread of cancer cells gives rise to peritoneal carcinomatosis which, without special treatments, is a fatal manifestation of these diseases. In order to control peritoneal carcinomatosis cytoreductive surgery to remove gross disease is combined with perioperative intraperitoneal and perioperative intravenous chemotherapy to eradicate microscopic residual disease. Chemotherapy agents are selected to be administered by the intraperitoneal or intravenous route based on their pharmacologic properties. A peritoneal- plasma barrier which retards the clearance of high molecular weight chemotherapy from the peritoneal cavity results in a large exposure of small cancer nodules on abdominal and pelvic surfaces. Tissue penetration is facilitated by moderate hyperthermia (41-42°C) of the intraperitoneal chemotherapy solution. A constant dose of chemotherapy agent and volume of carrier solution based on body surface area allows prediction of systemic drug exposure and systemic toxicity. Timing of the chemotherapy as a planned part of the surgical procedure to maximize exposure of all peritoneal surfaces is crucial to success.
Keywords: Intraperitoneal chemotherapy, 5-fluorouracil, doxorubicin, mitomycin C, peritoneal-plasma barrier, appendiceal cancer, colorectal cancer, peritoneal mesothelioma, ovarian cancer
Current Drug Discovery Technologies
Title: Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Volume: 6 Issue: 1
Author(s): Kurt Van der Speeten, Oswald Anthony Stuart and Paul H. Sugarbaker
Affiliation:
Keywords: Intraperitoneal chemotherapy, 5-fluorouracil, doxorubicin, mitomycin C, peritoneal-plasma barrier, appendiceal cancer, colorectal cancer, peritoneal mesothelioma, ovarian cancer
Abstract: The surfaces of the abdomen and pelvis are an important anatomic site for the dissemination of gastrointestinal and gynecologic malignancy. This transcoelomic spread of cancer cells gives rise to peritoneal carcinomatosis which, without special treatments, is a fatal manifestation of these diseases. In order to control peritoneal carcinomatosis cytoreductive surgery to remove gross disease is combined with perioperative intraperitoneal and perioperative intravenous chemotherapy to eradicate microscopic residual disease. Chemotherapy agents are selected to be administered by the intraperitoneal or intravenous route based on their pharmacologic properties. A peritoneal- plasma barrier which retards the clearance of high molecular weight chemotherapy from the peritoneal cavity results in a large exposure of small cancer nodules on abdominal and pelvic surfaces. Tissue penetration is facilitated by moderate hyperthermia (41-42°C) of the intraperitoneal chemotherapy solution. A constant dose of chemotherapy agent and volume of carrier solution based on body surface area allows prediction of systemic drug exposure and systemic toxicity. Timing of the chemotherapy as a planned part of the surgical procedure to maximize exposure of all peritoneal surfaces is crucial to success.
Export Options
About this article
Cite this article as:
Speeten Van der Kurt, Stuart Anthony Oswald and Sugarbaker H. Paul, Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy, Current Drug Discovery Technologies 2009; 6 (1) . https://dx.doi.org/10.2174/157016309787581084
DOI https://dx.doi.org/10.2174/157016309787581084 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Two Novel GPER Agonists Induce Gene Expression Changes and Growth Effects in Cancer Cells
Current Cancer Drug Targets Pharmacogenomics of Breast Cancer Targeted Therapy: Focus on Recent Patents
Recent Patents on DNA & Gene Sequences MEET THE GUEST EDITOR [Hot Topic: Modern Omics-Based Platform for High Throughput Screening for Novel Drug Targets (Part 2) (Guest Editor: Canhua Huang)]
Combinatorial Chemistry & High Throughput Screening Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Regenerating the Womb: The Good, Bad and Ugly Potential of the Endometrial Stem Cells
Current Regenerative Medicine (Discontinued) Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Current Medicinal Chemistry Editorial [Hot Topic: Surgical Treatment of Endometrial Cancer (Guest Editor: Maite Cusido Gimferrer)]
Current Women`s Health Reviews Challenges in Diagnosis of Reproductive Dysfunction
Current Women`s Health Reviews Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools
Current Drug Targets Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry Isoflavones and Bone Health
Current Women`s Health Reviews Genetics Talks to Epigenetics? The Interplay Between Sequence Variants and Chromatin Structure
Current Genomics Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women
Current Pharmaceutical Design Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens
Recent Patents on Anti-Cancer Drug Discovery Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry The Emergence of Non-coding RNAs as Versatile and Efficient Therapeutic Tools
Current Gene Therapy